1Beatson GT. On the treatment of inoper- able cases of carcinoma of the mamma: Suggestions for a new method of treat-ment with illustrative eases[J]. Lancet, 1896, 2: 104-107.
2Valenzuela M, Julian TB. Neoadjuvant hamaonaltherapy[J].Breast, 2008,14(3)979-283.
3Mathew J, Asgeirsson KS, Jackson LR, et al. Neoadjuvant endocrine treatment in primary breast cancer-review of literature[J]. Breast, 2009, 18(6) : 339-344.
6Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kine- tics of r esidual tu mor[J]. Cancer Res, 1979,39(10): 3861-3865.
7Chia YH, Ellis M J, Ma CX.Neoadjuvant endocrine therapy in primary breast can- cer: indications and use as a research tool[J]. British Journal of Cancer ,2010,103(6): 759-764.
9Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmeno- pausal breast cancer patients with letroz- ole: a randomized double-blind multicen- ter study [J]. Ann Oncol, 2001,12 (11): 1527-1532.
10Smith IE, Dowser M, Ebbs SR, et al. Neo- adjuvant treatment ofpostmenopausal bre- ast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Pre- operative Anastrozole, Tamoxifen, or Com- bined with Tamoxifen (IMPACT) multi- center double-blind randomized trial[J]. J Clin Oncol,2005, 23(22): 5108-5116.
二级参考文献43
1Krainiek-Strobel U E, Lichtenegger W, Wallwiener D, et al. Neoadjuvant letrozole in postmenopausal estrogen and/or pro gesterone receptor positive breast cancer: a phase Ⅱ b/Ⅲ trial to investigate optimal duration of preoperative endocrine therapy [J]. BMC Cancer,2008, 26(8) :62.
2Dixon J M, Renshaw L, Bellamy C, et al. The effects of neoad juvant anastrozole (Arimidex) on tumor volume in postmenopa usal women with breast cancer: a randomized, double-blind, single-center study[J]. Clin Cancer Res,2000,6(6) :2229-2235.
3Fasching P A, Heusinger K, Loehberg C R, ei al. Influence of mammographic density on the diagnostic accuracy of tumor size assessment and association with breast cancer tumor characteristics[J]. Eur J Radiol, 2006,60(3) : 398-404.
4Herrada J,Iyer R B, Atkinson E N, et al. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma[J]. Clin Cancer Res, 1997, 3 (9):1565 -1569.
5Sorlie T, Perou C M, Fan C, et al. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer[J].Mol Cancer Ther, 2006,5 ( 11 ) : 2914- 2918.
6Dowsett M, Smith I E, Ebbs S R, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer[J].J Natl Cancer Inst, 2007,99 (2) : 167-170.
7Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials[J]. Lancet, 2005,365(9472) : 1687-1717.
8Shimizu C, Ando M, Kouno T, et al. Current trends and controversies over pre-operative chemotherapy for women with operable breast cancer[J]. Jpn J Clin Oncol,2007,37(1):1-8.
9Liu S V, Melstrom L, Yao K, et al. Neoadjuvant therapy for breast cancer[J]. J Surg Oncol, 2010, 101(4): 283-291.
10Fennessy M, Bates T, MacRae K,et al. Late followup of a ran domized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer[J]. Br J Surg, 2004, 91(6),699-704.
